CNS SPECTRUMS®
The International Journal of Neuropsychiatric Medicine

SUBSCRIPTION INFORMATION

❑ YES! I want to continue my free subscription to CNS SPECTRUMS

Name:
Address:
E-mail:
Specialty:

FAX: 212.674.2891
MAIL:
CNS SPECTRUMS
MedWorks Media
665 Broadway, Suite 805
New York, NY 10012-2302

Signature:
Date:

PAID SUBSCRIPTIONS

❑ PRIMARY PSYCHIATRY

First in Applied Psychiatric Medicine

12 issues per year. One-year subscription rate: Domestic: $90; Foreign: $145; In-training: $50 (2000)

Billing

❑ Invoice Me
❑ Visa ❑ MC ❑ AmEx
Name:
Card #:
Exp. Date:

❑ TEN

The Economics of Neuroscience

12 issues per year. One-year subscription rate: Domestic: $120; Foreign: $185; In-training: $75

❑ ONE

Oncology Economics

12 issues per year. One-year subscription rate: Domestic: $120; Foreign: $185; In-training: $75

CONTINUING MEDICAL EDUCATION

Category 1 credits for psychiatrists, primary care physicians, and neurologists are available each month in *CNS Spectrums*, as well as on the MedWorks Media Web site:

www.medworksmedia.com

To participate, complete and mail the test and registration forms that are included in every issue of *CNS Spectrums*, or visit our Web site.

AUTHOR GUIDELINES 2000

Introduction

CNS Spectrums is a peer-reviewed journal that publishes original scientific literature and reviews on a wide variety of neuroscientific topics of interest to the clinician. *CNS Spectrums* publishes 12 issues in 2000. As the immense prevalence of comorbid diseases among patients seen by psychiatrists and neurologists increases, these physicians will jointly diagnose and treat the neuropsychiatrically ill. Our mission is to provide these physicians with an editorial package that will enhance and increase their understanding of neuropsychiatry; therefore, manuscripts that address crossover issues germane to neurology and psychiatry will be given immediate priority.

Scope of Manuscripts

CNS Spectrums will consider the following types of articles for publication:

Original Reports: Original reports present methodologically sound original data.

Reviews: Reviews are overview articles that summarize and synthesize the literature on various topics in a scholarly and clinically relevant fashion. Suitable topics include mood disorders, schizophrenia and related disorders, personality disorders, substance-use disorders, anxiety disorders, neuroscience, psychosocial aspects of psychiatry, child psychiatry, geriatric psychiatry, and other topics of interest to clinicians. nb: Original flowcharts designed to aid the clinician in diagnosis and treatment will be considered for publication in reviews and are encouraged.

Case Reports: Single or multiple case reports will be considered for publication.

Letters to the Editor: Letters will be considered for publication.

Manuscript Submissions

General Information: Four copies of the manuscript should be submitted to Eric Hollander, editor (or in Europe to Joseph Zohar, international editor), c/o MedWorks Media, 665 Broadway, Suite 805, New York, NY 10012; T: 212.328.0800, F: 212.328.0600. Authors are required to submit their manuscripts on computer disks. If possible, please provide them in MSWord Word for Windows in either a Macintosh or IBM format. (Saving the file in a lower version, eg, MSWord 3.0, is also encouraged.) Disks should be labeled with the word-processing program, title of paper, and first author's name.

Letters of permission to reproduce previously published material: All material reproduced from previously published copyrighted material must be accompanied by a letter of permission from the copyright holder. All such material should include a full credit line (eg, in the figure or table legend) acknowledging the original source. Any citation of unpublished material or personal communication should also be accompanied by a letter of permission for anyone who is not an author of the paper.

Peer review: Authors should provide five names of particularly qualified potential reviewers with no conflict of interest in reviewing the work. Contact information, including complete address, phone, fax numbers, E-mail address, and affiliations, should be included. The corresponding author will be notified by the editors when a decision regarding acceptance has been made. Accepted manuscripts and letters will be edited for clarity and style.

Manuscript Preparation

Length: Reviews should not exceed 20 manuscript pages (10,000 words). Original reports should not exceed 15–25 manuscript pages (6,250 words, maximum). Letters should not exceed 2–6 manuscript pages (1,500 words, maximum). Single case reports should not exceed 10–15 manuscript pages (3,750 words, maximum) and may be submitted with a photograph, if applicable. Diagnostic/treatment algorithms (see Reviews) should contain an extensive introduction, a flowchart or series of graphs that fill 8–12 journal pages, and a concise summary.

Spacing: One space should be left after commas and periods. Manuscripts should also be double-spaced.

Abstract: Authors should provide a brief abstract.

References: American Medical Association style. See the following examples:

1. Jones J. Necrotizing Candida esophagitis. *JAMA*. 1980;244:2190-2191.
2. Stryer L. *Biochemistry*. 2nd ed. San Francisco, Calif: WH Freeman Co; 1980:559-596.

Copyright: Materials are accepted for exclusive publication in *CNS Spectrums* and become the property of *CNS Spectrums*. Permission to reproduce material must be obtained from the publisher.

Disclosure of Commercial Interests

The authors must include a statement about all forms of support, including grant and drug company support. Such information may, at the editor's discretion, be shared with reviewers. If the article is accepted for publication, the editors will consult with the authors as to whether this information should be included in the published paper.

Reprints: Authors of reviews and original materials published in *CNS Spectrums* may order reprints of their articles directly from the publisher, James La Rossa Jr., MedWorks Media, New York, NY 10012; T:212.328.0800, F: 212.328.0600.

Continuing Medical Education requirements: Authors must submit four multiple-choice questions (two Type A and two Type K) with answers.

Submission Checklist

1. Original manuscript plus copies
2. Copies of permission letters to reproduce previously published and unpublished material
3. A brief abstract of article.
4. Two multiple-choice questions with answers
5. Disk labeled with the word-processing program, title of paper, and first author's name
6. Names and addresses of five potential reviewers.

https://doi.org/10.1017/S109285290002157X Published online by Cambridge University Press

GUIDE TO *DSM-IV* AND *ICD-10* CODES

	DSM-IV	*ICD-10*
Dementia of the Alzheimer Type, With Early Onset With Depressed Mood		
Specify if: With Behavioral Disturbance	290.13	F00.03
Dementia of the Alzheimer's Type, With Late Onset With Depressed Mood		
Specify if: With Behavioral Disturbance	290.21	F00.13
Delirium Due to: Indicate General Medical Condition	293.0	F05.0
Psychotic Disorder Due to: Indicate General Medical Condition With Delusions	293.81	F06.2
With Hallucinations	293.82	F06.0
Mood Disorder Due to: Indicate General Medical Condition	293.83	F06
Anxiety Disorder Due to: Indicate General Medical Condition	293.89	F06.4
Amnestic Disorder Due to: Indicate General Medical Condition	294.0	F02.8
Dementia NOS	294.8	F03
Amnestic Disorder NOS	294.8	R41.3
Schizophrenia	295	F20
Schizophrenia—Disorganized Type	295.10	F20.1
Schizophrenia—Catatonic Type	295.20	F20.2
Schizophrenia—Paranoid Type	295.30	F20.0
Schizophrenia—Residual Type	295.60	F20.5
Schizoaffective Disorder	295.70	F25
Schizophrenia—Undifferentiated Type	295.90	F20.3
Major Depressive Disorder	296	F32
Bipolar I Disorder	296	F30
Bipolar Disorder NOS	296.80	F39
Bipolar II Disorder	296.89	F31.8
Mood Disorder NOS	296.90	F39
Psychotic Disorder NOS	298.9	F29
Autistic Disorder	299.00	F84
Asperger's Disorder	299.80	F84.5
Pervasive Developmental Disorder NOS	299.80	F84.9
Anxiety Disorder NOS	300.00	F41.9
Panic Disorder Without Agoraphobia	300.01	F41
Generalized Anxiety Disorder	300.02	F41.1
Dissociative Identity Disorder	300.14	F44.81
Dissociative Disorder NOS	300.15	F44.9
Factitious Disorder NOS	300.19	F68.1
Panic Disorder With Agoraphobia	300.21	F40.01
Agoraphobia Without History of Panic Disorder	300.22	F40
Social Phobia	300.23	F40.1
Specific Phobia	300.29	F40.2
Obsessive-Compulsive Disorder	300.3	F42.8
Dysthymic Disorder	300.4	F34.1
Depersonalization Disorder	300.6	F48.1
Body Dysmorphic Disorder	300.7	F45.2
Somatization Disorder	300.81	F45.
Somatoform Disorder NOS	300.81	F45.9
Cyclothymic Disorder	301.13	F34
Alcohol Dependence	303.90	F10.2
Cocaine Dependence	304.20	F14.2
Cannabis Dependence	304.30	F12.2
Amphetamine Dependence	304.40	F15.2
Alcohol Abuse	305.00	F10.1
Cannabis Abuse	305.20	F12.1
Cocaine Abuse	305.60	F14.1
Amphetamine Abuse	305.70	F15.1
Stuttering	307.0	F98.5
Anorexia Nervosa	307.1	F50
Tic Disorder NOS	307.20	F95.9
Tourette Disorder	307.23	F95.2
Primary Insomnia	307.42	F51.0
Primary Hypersomnia	307.44	F51.1
Sleepwalking Disorder	307.46	F51.3
Dyssomnia NOS	307.47	F51.9
Nightmare Disorder	307.47	F51.5
Parasomnia NOS	307.47	F51.8
Eating Disorder NOS	307.50	F50.9
Bulimia Nervosa	307.51	F50.2
Feeding Disorders of Infancy or Early Childhood	307.59	F98.2
Communication Disorder NOS	307.9	F80.9
Posttraumatic Stress Disorder	309.81	F43.1
Depressive Disorder NOS	311	F32.9
Impulse-Control Disorder NOS	312.30	F63.9
Pathological Gambling	312.31	F63.0
Pyromania	312.33	F63.1
Kleptomania	312.34	F63.2
Trichotillomania	312.39	F63.3
Disruptive Behavior Disorder NOS	312.9	F91.9
Attention-Deficit/Hyperactivity Disorder, Combined Type	314.01	F90
Attention-Deficit/Hyperactivity Disorder NOS	314.9	F90.9
Learning Disorder NOS	315.9	F81.9
Developmental Coordination Disorder	315.4	F82
Narcolepsy	347	G47.4
Sleep Disorder Due to: Indicate General Medical Condition	780	G47
Delirium NOS	780.09	F05.9

https://doi.org/10.1017/S109285290002157X Published online by Cambridge University Press

CNS SPECTRUMS® The International Journal of Neuropsychiatric Medicine

FAXBACK RESPONSE

Name:

Address:

E-mail:

Specialty:

FAX: 212.674.2891

MAIL:

CNS SPECTRUMS
Medworks Media
665 Broadway, Suite 805
New York, NY 10012-2302

Signature: Date:

Your comments are important to us. This easy-to-use form provides you with the opportunity to express your opinions. Our goal is to make ***CNS Spectrums*** your source for practical and clinical neuropsychiatric information. By filling out this FaxBack form, you will enable us to incorporate your views about our editorial content in future issues. Please fill out this form in its entirety. Thank you.

1. On a scale of 1 to 5 (1=Poor, 5=Excellent), please indicate your level of interest and/or satisfaction with the editorial content in this issue.

Cover Story

1 2 3 4 5

Departments

CNS News

1 2 3 4 5

CME

1 2 3 4 5

2. Which areas of neuropsychiatry would you like us to cover in the future?

3. Please describe your reading pattern for this issue:
- ❍ cover to cover
- ❍ skim Table of Contents
- ❍ select items of interest
- ❍ skim text
- ❍ did not read

4. On a scale of 1 to 5 (1=Incomplete, 5=Comprehensive), how would you describe the depth of coverage for this issue?

1 2 3 4 5

5. Any other comments?

6. Please indicate your title:
- ❍ psychiatrist
- ❍ neurologist

When you send us this form, you'll receive one complimentary slide library and one complimentary reference material. Please make your selection below.

SLIDE LIBRARIES

- ❑ *Current Uses of Dopamine Agonists*
- ❑ *Monotherapeutic Uses for Dopamine Agonists*
- ❑ *Diagnosis and Treatment of Premenstrual Dysphoric Disorder*
- ❑ *Managing Psychiatric Illness in the Elderly*
- ❑ *Current Treatments in Alzheimer Disease*
- ❑ *Optimal Use of Antidepressants*
- ❑ *New Developments in the Treatment of Epilepsy*
- ❑ *Immunogenicity of Botulinum Toxin Therapy*
- ❑ *The Use of Anticonvulsants in the Treatment of Neuropathic Pain*
- ❑ *Overview of Social Anxiety Disorder (Social Phobia): Recognition and Treatment*
- ❑ *Advances in Diagnosis and Treatment of PTSD*
- ❑ *Current Treatments of ADHD*
- ❑ *Current and Emerging Treatments for Cervical Dystonia*

REFERENCE MATERIALS

- ❑ *The Black Book of Psychotropic Dosing and Monitoring 2000*

VENLAFAXINE HCl

EFFEXOR® XR

EXTENDED RELEASE CAPSULES

Brief Summary
See package insert for full prescribing information.
Indications and Usage: Effexor XR is indicated for the treatment of depression and for the treatment of Generalized Anxiety Disorder (GAD).
Contraindications: Effexor XR is contraindicated in patients known to be hypersensitive to venlafaxine hydrochloride. Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated (see **"Warnings"**).
Warnings: POTENTIAL FOR INTERACTION WITH MONOAMINE OXIDASE INHIBITORS—**Adverse reactions, some of which were serious, have been reported in patients who have recently been discontinued from an MAOI and started on venlafaxine, or who have recently had venlafaxine therapy discontinued prior to initiation of an MAOI. *These reactions have included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness,* hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death. In patients receiving antidepressants with pharmacological properties similar to venlafaxine in combination with an MAOI, there have also been reports of serious, sometimes fatal, reactions. For a selective serotonin reuptake inhibitor, these reactions have included hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. Some cases presented with features resembling neuroleptic malignant syndrome. Severe hyperthermia and seizures, sometimes fatal, have been reported in association with the combined use of tricyclic antidepressants and MAOIs. These reactions have also been reported in patients who have recently discontinued these drugs and have been started on an MAOI. The effects of combined use of venlafaxine and MAOIs have not been evaluated in humans or animals. Therefore, because venlafaxine is an inhibitor of both norepinephrine and serotonin reuptake, it is recommended that Effexor XR (venlafaxine hydrochloride) extended release capsules not be used in combination with an MAOI, or within at least 14 days of discontinuing treatment with an MAOI. Based on the half-life of venlafaxine, at least 7 days should be allowed after stopping venlafaxine before starting an MAOI.**
SUSTAINED HYPERTENSION—Venlafaxine is associated with sustained increases in blood pressure in some patients. Among patients treated with 75-375 mg per day of Effexor XR in premarketing depression studies, 3% experienced sustained hypertension [defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥ 90 mm Hg and ≥ 10 mm Hg above baseline for 3 consecutive on-therapy visits]. Among patients treated with 75-225 mg per day of Effexor XR in premarketing GAD studies, 0.4% (2/476) experienced sustained hypertension. Experience with immediate release venlafaxine showed that sustained hypertension was dose related, increasing from 3-7% at 100-300 mg per day to 13% at doses above 300 mg per day. An insufficient number of patients received mean doses of Effexor XR >300 mg/day to fully evaluate the incidence of sustained blood pressure at these higher doses. In premarketing depression and GAD studies, 0.7% and 0.4% of the Effexor XR-treated patients, respectively, discontinued treatment because of elevated blood pressure. It is recommended that patients receiving Effexor XR have regular monitoring of blood pressure. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.
Precautions: GENERAL—*Insomnia and Nervousness:* Treatment-emergent insomnia and nervousness have been reported for patients treated with Effexor XR. Insomnia and nervousness each led to drug discontinuation in 0.9% of the patients treated with Effexor XR in Phase 3 depression studies. In Phase 3 GAD trials, insomnia and nervousness *led to drug discontinuation in 5% and 3%, respectively, of the patients treated with Effexor XR.*
Changes in Appetite/Weight: Treatment-emergent anorexia has been reported in short-term depression and anxiety studies. A loss of 5% or more of body weight occurred in 7% of Effexor XR-treated and 2% of placebo-treated patients in placebo-controlled depression trials. A loss of 7% or more of body weight occurred in 3% of the Effexor XR-treated and 0% of the placebo-treated patients in placebo-controlled GAD trials.
Activation of Mania/Hypomania: Mania or hypomania has occurred during short-term depression studies. Effexor XR should be used cautiously in patients with a history of mania.
Seizures: No seizures occurred among Effexor XR-treated patients in short-term trials. In all premarketing depression trials with Effexor, seizures were reported in 0.3% of venlafaxine-treated patients. Use Effexor XR cautiously in patients with a history of seizures. Discontinue in any patient who develops seizures.
Suicide: The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Closely supervise high-risk patients during initial drug therapy. Prescriptions for Effexor XR should be written for the smallest quantity of capsules consistent with good patient management to reduce the risk of overdose. The same precautions observed when treating patients with depression should be observed when treating patients with GAD.
Use in Patients With Concomitant Illness: Premarketing experience with venlafaxine in patients with concomitant systemic illness is limited. Use Effexor XR cautiously in patients with diseases or conditions that could affect hemodynamic responses or metabolism. Venlafaxine has not been evaluated in patients with recent history of MI or unstable heart disease. In short-term depression studies electrocardiographic changes in corrected QT interval (QTc) for Effexor XR-treated patients showed an increase of 4.7 msec. In these same trials, the mean change from baseline heart rate for Effexor XR-treated patients was 4 beats per minute. In short-term GAD studies, mean changes in QTc for Effexor XR-treated patients did not differ significantly from placebo. The mean change from baseline heart rate for Effexor XR-treated patients in anxiety studies was 3 beats per minute. The clinical significance of these changes is unknown. In patients with renal impairment (GFR=10-70 mL/min) or cirrhosis of the liver, the clearances of venlafaxine and its active metabolites were decreased, thus prolonging the elimination half-lives. A lower dose may be necessary; use with caution in such patients.
INFORMATION FOR PATIENTS—Clinical studies in healthy individuals revealed no clinically significant impairment of psychomotor, cognitive, or complex behavior performance. However, caution patients about operating hazardous machinery, including automobiles, until they are reasonably sure that venlafaxine does not adversely affect their abilities. Tell patients to 1) notify their physician if they become pregnant or intend to become pregnant during therapy, or if they are nursing; 2) inform physician about other prescription or over the counter medications they are taking or plan to take; 3) avoid alcohol while taking Effexor XR; 4) notify their physician if they develop a rash, hives, or related allergic phenomena.
LABORATORY TESTS: There are no specific laboratory tests recommended.
DRUG INTERACTIONS—*Cimetidine:* Use with caution when administering venlafaxine with cimetidine to patients with pre-existing hypertension or hepatic dysfunction, and the elderly.
Haloperidol: Venlafaxine (150 mg/day) decreased total oral-dose clearance (Cl/F) of haloperidol which resulted in a 70% increase in haloperidol AUC. The haloperidol C_{max} increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life was unchanged.
Drugs Inhibiting Cytochrome P4502D6 Metabolism: Venlafaxine is metabolized to its active metabolite, O-desmethylvenlafaxine (ODV), via cytochrome P4502D6. Drugs inhibiting this isoenzyme have the potential to increase plasma concentrations of venlafaxine and decrease concentrations of ODV. However, since the composite plasma levels of venlafaxine and ODV are essentially unchanged in CYP2D6 poor metabolizers, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.
The concomitant use of venlafaxine with a drug treatment(s) that potentially inhibits both CYP2D6 and CYP3A4, the primary metabolizing enzymes for venlafaxine, has not been studied. Therefore, caution is advised should a patient's therapy include venlafaxine and any agent(s) that produce simultaneous inhibition of these two enzyme systems.
Drugs Metabolized by Cytochrome P450 Isoenzymes: Studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2 and CYP3A4 (*in vitro* and *in vivo*), CYP2C9 (*in vitro*), or CYP2C19 (*in vivo*).
Imipramine—Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. However, desipramine AUC, C_{max} and C_{min} increased by about 35% in the presence of venlafaxine. The 2-OH-desipramine AUC's increased by 2.5-4.5 fold. Imipramine did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of elevated 2-OH-desipramine levels is unknown.
Risperidone—Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).
Monoamine Oxidase Inhibitors: See **"Contraindications"** and **"Warnings."**
CNS-Active Drugs: Use of venlafaxine with CNS-active drugs has not been systematically evaluated; use caution when administering Effexor XR with such drugs.
Postmarketing Spontaneous Drug Interaction Reports: See **"ADVERSE REACTIONS," "Postmarketing Reports."**
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY—*Carcinogenesis:* There was no increase in tumors in 18-month studies in mice given up to 120 mg/kg/day [1.7 times the maximum recommended human dose (MRHD) mg/m² basis] or in 24-month studies in rats given up to 120 mg/kg/day.
Mutagenesis: Venlafaxine and ODV were not mutagenic in the Ames reverse mutation assay in Salmonella bacteria or the Chinese hamster ovary/HGPRT mammalian cell forward gene mutation assay. Venlafaxine was not clastogenic in several assays. ODV elicited a clastogenic response in the *in vivo* chromosomal aberration assay in rat bone marrow.
Impairment of Fertility: No effects on reproduction or fertility in rats were noted at oral doses of up to 2 times the MRHD on a mg/m² basis.
PREGNANCY—*Teratogenic Effects—Pregnancy Category C.* Reproduction studies in rats given 2.5 times, and rabbits given 4 times the MRHD (mg/m² basis) revealed no malformations in offspring. However, in rats given 2.5 times the MRHD, there was a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation when dosing began during pregnancy and continued until weaning. There are no adequate and well-controlled studies in pregnant women; use Effexor XR during pregnancy only if clearly needed.
LABOR, DELIVERY, NURSING—The effect on labor and delivery in humans is unknown. Venlafaxine and ODV have been reported to be excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Effexor XR, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
PEDIATRIC USE—Safety and effectiveness in pediatric patients have not been established.
GERIATRIC USE—Approximately 4% and 3% of Effexor XR-treated patients in placebo-controlled premarketing depression and GAD trials, respectively, were 65 years of age or over. Of 2,897 Effexor-treated patients in premarketing phase depression studies, 12% were 65 years of age or over. No overall differences in effectiveness or safety were observed between geriatric patients and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. As with other antidepressants, several cases of hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH) have been reported, usually in the elderly.
Adverse Reactions: ASSOCIATED WITH DISCONTINUATION OF TREATMENT—Approximately 11% and 23% of Effexor XR patients in placebo-controlled clinical depression and GAD trials, respectively, discontinued treatment due to an adverse event. The most common events leading to discontinuation in at least 1% of patients and at least twice that *of placebo in depression trials included:* nausea, anorexia, dry mouth, dizziness, insomnia, and somnolence; in *U.S.* placebo-controlled depression trials included: hypertension, diarrhea, paresthesia, tremor, abnormal (mostly blurred) vision, and abnormal (mostly delayed) ejaculation; in GAD trials included: headache, asthenia, vasodilation, nausea, anorexia, dry mouth, dizziness, insomnia, nervousness, somnolence, thinking abnormal, tremor, and abnormal vision.
INCIDENCE IN CONTROLLED TRIALS—*Commonly Observed Adverse Events in Controlled Clinical Trials:* The most commonly observed adverse events associated with the use of Effexor XR in placebo-controlled depression trials (incidence of 5% or greater and incidence for Effexor XR at least twice that for placebo): nausea (31% vs. 12%), dizziness (20% vs. 9%), somnolence (17% vs. 8%), abnormal ejaculation (16% vs. <1%), sweating (14% vs. 3%), dry mouth (12% vs. 6%), nervousness (10% vs. 5%), anorexia (8% vs. 4%), abnormal dreams (7% vs. 2%), and tremor (5% vs. 2%). In U.S. placebo-controlled depression trials, the following were also reported with an incidence of at least 5% and at least twice that for placebo: impotence, anorgasmia, decreased libido, constipation, flatulence, insomnia, nervousness, tremor, abnormal vision, hypertension, vasodilation, and yawning. The most commonly observed adverse events associated with the use of Effexor XR in placebo-controlled GAD trials (incidence of 5% or greater and incidence for Effexor XR at least twice that for placebo): nausea (43% vs. 11%), dry mouth (23% vs. 5%), insomnia (22% vs. 11%), abnormal ejaculation (17% vs. 0%), anorexia (13% vs. 2%), constipation (12% vs. 5%), nervousness (12% vs. 5%), *sweating* (11% vs. <1%), *abnormal vision* (8% vs. 0%), *yawn* (6% vs. <1%), *impotence* (6% vs. 1%), decreased libido (6% vs. 2%), vasodilation (6% vs. 2%), vomiting (6% vs. 2%).
Adverse Events Occurring at an Incidence of 2% or More Among Effexor XR-Treated Patients: The following occurred in short-term, placebo-controlled depression trials (up to 12 weeks) with doses of 75 to 225 mg/day, at a frequency of 2% or more and greater than placebo. **Body as a Whole:** asthenia. **Cardiovascular:** vasodilation, hypertension. **Digestive:** nausea, constipation, anorexia, vomiting, flatulence. **Metabolic/Nutritional:** weight loss. **Nervous System:** dizziness, somnolence, insomnia, dry mouth, nervousness, abnormal dreams, tremor, depression, paresthesia, decreased libido, agitation. **Respiratory System:** pharyngitis, yawn. **Skin:** sweating. **Special Senses:** abnormal vision. **Urogenital System:** abnormal ejaculation, impotence, anorgasmia (female). The following occurred in short-term, placebo-controlled GAD trials (up to 8 weeks), with doses of 75 to 225 mg/day, at a frequency of 2% or more and greater than placebo. **Body as a Whole:** asthenia, infection, abdominal pain, fever, neck pain, chills. **Cardiovascular:** vasodilation, tachycardia. **Digestive:** nausea, anorexia, diarrhea, constipation, vomiting, flatulence. **Musculoskeletal System:** myalgia. **Nervous System:** dry mouth, insomnia, dizziness, somnolence, nervousness, decreased libido, abnormal dreams, tremor, paresthesia, thinking abnormal, trismus, twitching. **Respiratory System:** rhinitis, yawn, cough increased. **Skin:** sweating. **Special Senses:** abnormal vision. **Urogenital System:** abnormal *ejaculation, impotence, dysmenorrhea, orgasmic dysfunction (female), urinary frequency.*
Vital Sign Changes: In clinical depression and GAD trials, Effexor XR was associated with a mean increase in pulse rate of about 2 beats/min. (See the **"Sustained Hypertension"** section of **"Warnings"** for effects on blood pressure.)
Laboratory Changes: In clinical depression and GAD trials, Effexor XR was associated with a mean increase in serum cholesterol concentration of about 1.5 mg/dL and 2.5 mg/dL, respectively; clinical significance is unknown.
ECG Changes: (See the *"Use in Patients With Concomitant Illnesses"* section of **"Precautions"**.)
OTHER EVENTS OBSERVED DURING THE PREMARKETING EVALUATION OF EFFEXOR AND EFFEXOR XR—During premarketing assessment, multiple doses of Effexor XR or Effexor were administered to 4174 patients, and the following adverse events were reported. Note: "frequent" = events occurring in at least 1/100 patients; "infrequent" = 1/100 to 1/1000 patients; "rare" = fewer than 1/1000 patients. It is important to emphasize that although the events occurred during treatment with venlafaxine, they were not necessarily caused by it.
Body as a whole - **Frequent:** chest pain substernal; **Infrequent:** face edema, intentional injury, malaise, moniliasis, neck rigidity, pelvic pain, photosensitivity reaction, suicide attempt; **Rare:** appendicitis, carcinoma, cellulitis, withdrawal syndrome. Cardiovascular system - **Frequent:** migraine, postural hypotension; **Infrequent:** angina pectoris, arrhythmia, extrasystoles, hypotension, peripheral vascular disorder (mainly cold feet and/or cold hands), syncope, thrombophlebitis; **Rare:** *arteritis, first-degree atrioventricular block, bigeminy, bradycardia, bundle branch block, cerebral* ischemia, coronary artery disease, congestive heart failure, heart arrest, mitral valve disorder, mucocutaneous hemorrhage, myocardial infarct, pallor. Digestive system - **Frequent:** eructation, increased appetite; **Infrequent:** bruxism, colitis, dysphagia, tongue edema, esophagitis, gastritis, gastroenteritis, gastrointestinal ulcer, gingivitis, glossitis, rectal hemorrhage, hemorrhoids, melena, stomatitis, mouth ulceration; **Rare:** cheilitis, cholecystitis, cholelithiasis, hematemesis, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, ileitis, jaundice, intestinal obstruction, oral moniliasis, proctitis, increased salivation, soft stools, tongue discoloration. Endocrine system - **Rare:** goiter, hyperthyroidism, hypothyroidism, thyroid nodule, thyroiditis. Hemic and lymphatic system - **Frequent:** ecchymosis; **Infrequent:** anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocythemia, thrombocytopenia; **Rare:** basophilia, cyanosis, eosinophilia, lymphocytosis. Metabolic and nutritional - **Frequent:** edema, weight gain; **Infrequent:** alkaline phosphatase increased, glycosuria, hypercholesteremia, hyperglycemia, hyperuricemia, hypoglycemia, hypokalemia, SGOT increased, thirst; **Rare:** alcohol intolerance, bilirubinemia, BUN increased, creatinine increased, diabetes mellitus, dehydration, gout, hemochromatosis, hypercalciuria, hyperkalemia, hyperlipemia, hypernatremia, hyperphosphatemia, hypophosphatemia, hypoproteinemia, SGPT increased, uremia. Musculoskeletal system - **Frequent:** arthralgia; **Infrequent:** arthritis, arthrosis, bone pain, bone spurs, bursitis, leg cramps, myasthenia, tenosynovitis; **Rare:** pathological fracture, myopathy, osteoporosis, osteosclerosis, rheumatoid arthritis, tendon rupture. Nervous system - **Frequent:** amnesia, confusion, depersonalization, emotional lability, hypesthesia, vertigo; **Infrequent:** apathy, ataxia, circumoral paresthesia, CNS stimulation, euphoria, hallucinations, hostility, hyperesthesia, hyperkinesia, hypotonia, incoordination, libido increased, manic reaction, myoclonus, neuralgia, neuropathy, paranoid reaction, psychosis, seizure, abnormal speech, stupor; **Rare:** akathisia, akinesia, alcohol abuse, aphasia, bradykinesia, buccoglossal syndrome, cerebrovascular accident, loss of consciousness, delusions, dementia, dystonia, facial paralysis, abnormal gait, Guillain-Barré Syndrome, hypokinesia, neuritis, nystagmus, psychotic depression, reflexes decreased, reflexes increased, suicidal ideation, torticollis. Respiratory system - **Frequent:** dyspnea; **Infrequent:** asthma, chest congestion, epistaxis, hyperventilation, laryngismus, laryngitis, pneumonia, voice alteration; **Rare:** atelectasis, hemoptysis, hypoventilation, hypoxia, pleurisy, pulmonary embolus, sleep apnea. Skin and appendages - **Frequent:** rash, pruritus; **Infrequent:** acne, alopecia, brittle nails, contact dermatitis, dry skin, eczema, skin hypertrophy, maculopapular rash, psoriasis, urticaria; **Rare:** erythremia nodosum, exfoliative dermatitis, lichenoid dermatitis, hair discoloration, skin discoloration, furunculosis, hirsutism, leukoderma, pustular rash, vesiculobullous rash, seborrhea, skin atrophy, skin striae. Special senses - **Frequent:** abnormality of accommodation, mydriasis, taste perversion; **Infrequent:** cataract, conjunctivitis, corneal lesion, diplopia, dry eyes, exophthalmos, eye pain, hyperacusis, otitis media, parosmia, photophobia, taste loss, visual field defect; **Rare:** blepharitis, chromatopsia, conjunctival edema, deafness, glaucoma, retinal hemorrhage, subconjunctival hemorrhage, keratitis, labyrinthitis, miosis, papilledema, decreased pupillary reflex, otitis externa, scleritis, uveitis. Urogenital system - **Frequent:** metrorrhagia,* prostatitis,* urination impaired, vaginitis*; **Infrequent:** albuminuria, amenorrhea,* cystitis, dysuria, hematuria, female lactation,* leukorrhea,* menorrhagia,* nocturia, bladder pain, breast pain, polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, vaginal hemorrhage*; **Rare:** abortion,* anuria, breast engorgement, breast enlargement, fibrocystic breast, calcium crystalluria, cervicitis,* ovarian cyst,* prolonged erection,* gynecomastia (male),* hypomenorrhea,* kidney calculus, kidney pain, kidney function abnormal, mastitis, menopause,* pyelonephritis, oliguria, salpingitis,* urolithiasis, uterine hemorrhage,* uterine spasm.* (*Based on the number of men and women as appropriate.)
Postmarketing Reports: Voluntary reports of other adverse events temporally associated with the use of Effexor (the immediate release form of venlafaxine) that have been received since market introduction and that may have no causal relationship with the use of Effexor include the following: agranulocytosis, anaphylaxis, aplastic anemia, catatonia, congenital anomalies, CPK increased, deep vein thrombophlebitis, delirium, EKG abnormalities (such as atrial fibrillation, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia), epidermal necrosis/Stevens-Johnson Syndrome, erythema multiforme, extrapyramidal symptoms (including tardive dyskinesia), hemorrhage (including eye and gastrointestinal bleeding), hepatic events (including GGT elevation; abnormalities of unspecified liver function tests; liver damage, necrosis, or failure; and fatty liver), involuntary movements, LDH increased, neuroleptic malignant syndrome-like events (including a case of a 10-year-old who may have been taking methylphenidate, was treated and recovered), pancreatitis, panic, prolactin increased, renal failure, serotonin syndrome, shock-like electrical sensations (in some cases, subsequent to the discontinuation of Effexor or tapering of dose), and syndrome of inappropriate antidiuretic hormone secretion (usually in the elderly).
There have been reports of elevated clozapine levels that were temporally associated with adverse events, including seizures, following the addition of venlafaxine. There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.
Drug Abuse and Dependence: Effexor® XR is not a controlled substance. Evaluate patients carefully for history of drug abuse and observe such patients closely for signs of venlafaxine misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).
OVERDOSAGE: In premarketing evaluation of Effexor XR for depression, there were 2 reports of acute overdosage (6 g of Effexor XR with 2.5 mg of lorazepam, and 2.85 g of Effexor XR). Both recovered without sequelae. In premarketing evaluation of Effexor, there were 14 reports of acute overdosage (highest dose was 6.75 g). All patients recovered without sequelae. Most patients reported no symptoms. Symptoms observed included somnolence, generalized convulsions, prolongation of QTc to 500 msec (compared with 405 msec at baseline) in one case, and mild sinus tachycardia. In premarketing evaluation of Effexor XR for GAD, there were 2 reports of acute overdosage (0.75 g of Effexor XR and 200 mg of paroxetine and 50 mg of zolpidem, and 1.2 g of Effexor XR). Both recovered without sequelae.
In postmarketing experience, there have been reports of fatalities in patients taking overdoses of venlafaxine, predominantly in combination with alcohol and/or other drugs.
Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for venlafaxine are known. In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the *Physicians' Desk Reference®* (PDR).
SWITCHING PATIENTS TO OR FROM A MONOAMINE OXIDASE INHIBITOR: At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with Effexor XR. In addition, at least 7 days should be allowed after stopping Effexor XR before starting an MAOI (See **"Contraindications"** and **"Warnings"**).
Please consult full prescribing information for detailed dosing instructions.
This brief summary is based on the circular 4876-4, issued March 22, 1999.

WYETH-AYERST LABORATORIES
Philadelphia, PA 19101

79345-00



Depression
or
Generalized Anxiety Disorder

to better

to well



Get your patients beyond better

- Working on both serotonin and norepinephrine, the unique formulation of EFFEXOR XR offers more of your patients the ability to achieve remission—full symptom resolution.[1,2]

Need proof? Call 1-888-EFFEXOR XR.

Visit us at www.EFFEXORXR.com

Please see brief summary of Prescribing Information on the next page.

ONCE-DAILY

VENLAFAXINE HCl

EFFEXOR® XR *EXTENDED RELEASE CAPSULES*

Beyond better.

The efficacy and safety of EFFEXOR XR for pediatric use have not been established.

EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). EFFEXOR XR should not be used in combination with an MAOI or within at least 14 days of discontinuing treatment with an MAOI; at least 7 days should be allowed after stopping EFFEXOR XR before starting an MAOI.

The most common adverse events reported in EFFEXOR XR placebo-controlled depression trials (incidence ≥10% and ≥2× that of placebo) were nausea, dizziness, somnolence, abnormal ejaculation, sweating, dry mouth, and nervousness; and in GAD trials were nausea, dry mouth, insomnia, abnormal ejaculation, anorexia, constipation, nervousness, and sweating.

Treatment with venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Three percent of EFFEXOR XR patients in depression studies (doses of 75 to 375 mg/day) and 0.4% in GAD studies (doses of 75 to 225 mg/day) had sustained BP elevations. Less than 1% discontinued treatment because of elevated BP. Regular BP monitoring is recommended.

References: 1. Data on file, Wyeth-Ayerst Laboratories, Philadelphia, Pa. **2.** Ferrier IN. Treatment of major depression: is improvement enough? *J Clin Psychiatry.* 1999;60(suppl 6):10-14.

https://doi.org/10.1017/S109285290002157X Published online by Cambridge University Press